Bio-Techne to acquire Exosome Diagnostics
Bio-Techne, a bio-tech and clinical diagnostic holding firm, has recently announced the acquisition of Boston-based Exosome Diagnostics for USD 250m in cash, a sum which could increase by up to USD 325m contingent on the reaching of unspecified milestones. Exosome Diagnostics produces non-invasive liquid biopsy tests, which offer an alternative to surgical biopsies by identifying nanoparticles in fluids. These diagnostic tests are currently used to identify prostate cancer, but Exosome plans to expand to a host of other hard to diagnose cancers. Bio-Techne, valued at USD 5.9bn, has closed 13 other acquistions in the past 5 years. Read more here.